Thymic cellularity and CD8+ expansion in Stat5b TG mice at 2 time intervals
| . | 0 to 10 wk . | 10 to 20 wk . | ||||
|---|---|---|---|---|---|---|
| Thymic cellularity, 10−6 (SEM) . | CD8, % (SEM) . | n . | Thymic cellularity, 10−6(SEM) . | CD8, % (SEM) . | n . | |
| WT | 106 (13) | 6 (0.6) | 28 | 74 (13) | 9 (2.3) | 10 |
| 5bTG WT | 128 (14) | 7 (1.2) | 16 | 55 (6) | 17* (3.7) | 8 |
| β2m−/− | 88 (9) | 3 (0.7 | 5 | 76* (13) | 4 (0.9) | 8 |
| 5bTG β2m−/− | 106 | 5 | 1 | 41 (8) | 13* (4) | 9 |
| TCRα−/− | 107 (26) | 3 (0.7) | 4 | 85 | 5 | 1 |
| 5bTG TCRα−/− | 165 | 5 | 1 | 198 (83) | 10* (0.3) | 2 |
| preTCRα−/− | 6 (2) | 3 (1.4) | 4 | 5 (0.3) | 6 (1.3) | 4 |
| 5bTG preTCRα−/− | 30* (10) | 9* (0.4) | 2 | 10 (5.5) | 7 (3.2) | 2 |
| . | 0 to 10 wk . | 10 to 20 wk . | ||||
|---|---|---|---|---|---|---|
| Thymic cellularity, 10−6 (SEM) . | CD8, % (SEM) . | n . | Thymic cellularity, 10−6(SEM) . | CD8, % (SEM) . | n . | |
| WT | 106 (13) | 6 (0.6) | 28 | 74 (13) | 9 (2.3) | 10 |
| 5bTG WT | 128 (14) | 7 (1.2) | 16 | 55 (6) | 17* (3.7) | 8 |
| β2m−/− | 88 (9) | 3 (0.7 | 5 | 76* (13) | 4 (0.9) | 8 |
| 5bTG β2m−/− | 106 | 5 | 1 | 41 (8) | 13* (4) | 9 |
| TCRα−/− | 107 (26) | 3 (0.7) | 4 | 85 | 5 | 1 |
| 5bTG TCRα−/− | 165 | 5 | 1 | 198 (83) | 10* (0.3) | 2 |
| preTCRα−/− | 6 (2) | 3 (1.4) | 4 | 5 (0.3) | 6 (1.3) | 4 |
| 5bTG preTCRα−/− | 30* (10) | 9* (0.4) | 2 | 10 (5.5) | 7 (3.2) | 2 |
Mean thymic cellularity and percentage of CD8+ cells (SEM) in WT, β2m−/−, TCRα−/−, and pre-TCRα−/−mice with and without the Stat5b transgene are shown. Only mice without lymphoma as defined by criteria outlined in ″Generation of mice″ were included in the analysis. Because of tumor development in older mice, we do not have an expansion group beyond 20 weeks. Also shown are total numbers (n) in each group that met criteria for analysis; for example, there was only a single Stat5b TG/TCRα−/− mouse that met the criteria for not having lymphoma in the 0- to 10-week group.
Significant differences (P < .05) between the mice without and with the transgene.